Monday, August 24, 2020 4:57:22 PM
Testing will be around for a long while, and if Biocept's press release with AEGEA (who granted them exclusivity on some switch blocker patents) which stated they have a test kit that is next generation and can differentiate strains then they will have a competitive advantage.
I don't know what the current revenues are, but if that poster was correct and they are doing 2000 tests a day ( I dont buy it) then the revenue is massive and a nice addition to oncology. Even 1000 tests a day is huge volume.
Recent BIOCQ News
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 11/20/2023 01:47:57 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM